UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Reducing Sugared Fruit Drinks in Alaska Native Children

Not Applicable

Completed

Conditions: Healthy

Interventions: Behavioral: Education and self-efficacy coaching

First Posted Date: 2022-02-02

Last Posted Date: 2024-07-29

Lead Sponsor: University of Washington

Target Recruit Count: 334

Registration Number: NCT05219448

Locations: 🇺🇸
University of Washington School of Dentistry, Seattle, Washington, United States

Triglyceride Effects on Blood Flow in the Human Brain

Not Applicable

Completed

Conditions: Alzheimer Disease

Interventions: Dietary Supplement: Lipid drink

First Posted Date: 2022-02-01

Last Posted Date: 2023-02-08

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT05218018

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Impact of Male Provider Phone Calls to Increase Men's Clinic Linkage After HIVST

Not Applicable

Conditions: Linkage to Care
PMTCT
PrEP
ART Adherence
HIV

Interventions: Diagnostic Test: POC viral load testing
Other: Wellness visit services for male partners

First Posted Date: 2022-01-18

Last Posted Date: 2022-11-08

Lead Sponsor: University of Washington

Target Recruit Count: 100

Registration Number: NCT05194085

Locations: 🇺🇬
Infectious Disease Institute, Kampala, Uganda

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Limited Stage Lung Small Cell Carcinoma
Extensive Stage Lung Small Cell Carcinoma

Interventions: Drug: Bomedemstat
Biological: Atezolizumab

First Posted Date: 2022-01-14

Last Posted Date: 2024-05-06

Lead Sponsor: University of Washington

Target Recruit Count: 3

Registration Number: NCT05191797

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

CHV-NEO: Community-based Digital Communication to Support Neonatal Health

Not Applicable

Recruiting

Conditions: Neonatal Death
Perinatal Death

Interventions: Behavioral: CHV-NEO

First Posted Date: 2022-01-12

Last Posted Date: 2024-01-16

Lead Sponsor: University of Washington

Target Recruit Count: 2000

Registration Number: NCT05187897

Locations: 🇰🇪
Kenyatta National Hospital, Kisumu, Kenya

Smart Eyewear to Automatically Detect Drug Delivery Events

Recruiting

Conditions: Smart Eyewear

First Posted Date: 2022-01-11

Last Posted Date: 2024-05-08

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT05184660

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Phase 4

Recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Breast Adenocarcinoma
Invasive Breast Carcinoma of No Special Type
Anatomic Stage II Breast Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Letrozole
Other: Questionnaire Administration

First Posted Date: 2022-01-11

Last Posted Date: 2024-07-19

Lead Sponsor: University of Washington

Target Recruit Count: 60

Registration Number: NCT05183828

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

eLearning for Suicide Prevention

Not Applicable

Completed

Conditions: Suicide

Interventions: Behavioral: eLearning Training in Suicide Safety Planning

First Posted Date: 2022-01-05

Last Posted Date: 2023-12-18

Lead Sponsor: University of Washington

Target Recruit Count: 19

Registration Number: NCT05178121

Locations: 🇺🇸
Harborview Medical Center, Seattle, Washington, United States

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma
Grade 1 Follicular Lymphoma
Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Indolent B-Cell Non-Hodgkin Lymphoma
Marginal Zone Lymphoma
Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue

Interventions: Biological: Mosunetuzumab
Biological: Obinutuzumab
Drug: Polatuzumab Vedotin
Procedure: FDG-Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection

First Posted Date: 2021-12-27

Last Posted Date: 2024-11-01

Lead Sponsor: University of Washington

Target Recruit Count: 42

Registration Number: NCT05169658

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Frontline Clinician Psilocybin Study

Phase 3

Completed

Conditions: Burnout, Caregiver
Burnout, Professional
COVID-19
Depression
Post Traumatic Stress Disorder
Moral Injury

Interventions: Drug: Psilocybin (Usona Institute)
Drug: Active placebo

First Posted Date: 2021-12-20

Last Posted Date: 2024-08-28

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT05163496

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy